全球基因治疗市场规模、份额、趋势和成长分析报告（2026-2034）

基因治疗市场预计将从 2025 年的 85 亿美元成长到 2034 年的 421.1 亿美元，2026 年至 2034 年的复合年增长率为 19.45%。

受生物技术进步和人们对治疗遗传疾病日益增长的兴趣的推动，全球基因治疗市场正经历显着增长。基因治疗是指透过修改或取代缺陷基因来治疗或预防疾病，为过去被认为无法治癒的疾病提供了潜在的治疗方法。研发投入的增加是推动市场扩张的主要动力。

关键驱动因素包括遗传疾病盛行率的不断上升、对个人化医疗日益增长的需求以及CRISPR等基因编辑技术的进步。在有利的法规结构支持下，製药和倡议正在积极开发创新治疗方法。此外，合作关係和资金筹措正在加速临床试验和产品开发。

随着新治疗方法和改进型递送系统的推出，预计未来市场将持续扩张。病毒载体和非病毒疗法的进步将提升安全性和有效性。随着科学研究的不断深入，基因治疗市场有望迎来变革性成长，并对全球医疗保健产生重大影响。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球基因治疗市场：依适应症划分

• 市场分析、洞察与预测
• 大B细胞淋巴瘤
• 多发性骨髓瘤
• 脊髓性肌肉萎缩症（SMA）
• 急性淋巴性白血病（ALL）
• 恶性黑色素瘤（病变）
• 遗传性视网膜疾病
• 重型β地中海贫血/镰状细胞疾病
• 其他的

第五章 全球基因治疗市场：依载体类型划分

• 市场分析、洞察与预测
• 慢病毒
• 逆转录病毒和γ逆转录病毒
• AAV
• 改良型单纯疱疹病毒
• 腺病毒
• 其他的

第六章：全球基因治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 静脉
• 其他的

第七章 全球基因治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Amgen Inc
  • Novartis AG
  • F. Hoffmann-La Roche
  • Gilead Sciences Inc
  • Bluebird Bio Inc
  • Bristol-Myers Squibb Company
  • Legend Biotech
  • BioMarin
  • UniQure NV
  • Merck & Co
  • Sarepta Therapeutics Inc

The Gene Therapy Market size is expected to reach USD 42.11 Billion in 2034 from USD 8.50 Billion (2025) growing at a CAGR of 19.45% during 2026-2034.

The global gene therapy market is witnessing significant growth due to advancements in biotechnology and increasing focus on treating genetic disorders. Gene therapy involves modifying or replacing defective genes to treat or prevent diseases, offering potential cures for conditions that were previously considered untreatable. Rising investments in research and development are significantly driving market expansion.

Key drivers include increasing prevalence of genetic disorders, growing demand for personalized medicine, and advancements in gene editing technologies such as CRISPR. Pharmaceutical and biotechnology companies are actively developing innovative therapies, supported by favorable regulatory frameworks. Additionally, collaborations and funding initiatives are accelerating clinical trials and product development.

Looking ahead, the market is expected to expand with the introduction of new therapies and improved delivery systems. Advances in viral vectors and non-viral methods will enhance safety and effectiveness. As scientific research continues to progress, the gene therapy market is poised for transformative growth and significant impact on global healthcare.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Indication

• Large B-Cell Lymphoma
• Multiple Myeloma
• Spinal Muscular Atrophy (SMA)
• Acute Lymphoblastic Leukemia (ALL)
• Melanoma (lesions)
• Inherited Retinal Disease
• Beta-Thalassemia Major/SCD
• Others

By Vector Type

• Lentivirus
• RetroVirus & gamma RetroVirus
• AAV
• Modified Herpes Simplex Virus
• Adenovirus
• Others

By Route of Administration

• Intravenous
• Others

COMPANIES PROFILED

• Amgen Inc, Novartis AG, F HoffmannLa Roche, Gilead Sciences Inc, bluebird bio Inc, BristolMyers Squibb Company, Legend Biotech, BioMarin, uniQure NV, Merck Co, Sarepta Therapeutics Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENE THERAPY MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Large B-Cell Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Multiple Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Spinal Muscular Atrophy (SMA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Acute Lymphoblastic Leukemia (ALL) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Melanoma (lesions) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Inherited Retinal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Beta-Thalassemia Major/SCD Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENE THERAPY MARKET: BY VECTOR TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Vector Type
• 5.2. Lentivirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. RetroVirus & gamma RetroVirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. AAV Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Modified Herpes Simplex Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Adenovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENE THERAPY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENE THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Indication
  • 7.2.2 By Vector Type
  • 7.2.3 By Route Of Administration
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Indication
  • 7.3.2 By Vector Type
  • 7.3.3 By Route Of Administration
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Indication
  • 7.4.2 By Vector Type
  • 7.4.3 By Route Of Administration
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Indication
  • 7.5.2 By Vector Type
  • 7.5.3 By Route Of Administration
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Indication
  • 7.6.2 By Vector Type
  • 7.6.3 By Route Of Administration
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GENE THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Amgen Inc
  • 9.2.2 Novartis AG
  • 9.2.3 F. Hoffmann-La Roche
  • 9.2.4 Gilead Sciences Inc
  • 9.2.5 Bluebird Bio Inc
  • 9.2.6 Bristol-Myers Squibb Company
  • 9.2.7 Legend Biotech
  • 9.2.8 BioMarin
  • 9.2.9 UniQure N.V
  • 9.2.10 Merck & Co
  • 9.2.11 Sarepta Therapeutics Inc